Johnson & Johnson Surprises with Profit Surge Amid Strong Darzalex Sales

In a remarkable performance that outshined analysts' expectations, Johnson & Johnson reported a significant boost in profits driven largely by the impressive sales of its cancer treatment drug, Darzalex. The healthcare giant has proven its resilience amid a competitive market landscape, showcasing not only strong product demand but also strategic management of its resources.

Continue reading